GSK Opens New Respiratory Manufacturing Facility

Article

The facility located in Ware, UK, will be used to manufacture GSK’s Ellipta inhaler.

GlaxoSmithKline (GSK) opened a £56 million (approximately $80.67 million) manufacturing facility in Ware, United Kingdom, according to an April 18, 2016 press announcement. The 4200-m2 facility will create 150 new jobs in the UK.

The Ware facility is the latest expansion of GSK’s Ellipta inhaler manufacturing. The company says they expect the opening of the facility to nearly double production of Ellipta inhalers to at least 37 million per year by 2017, 95% of which, the company said, will be exported.

Since 2013, over 400 roles will have been created at the manufacturing site in Ware, bringing the staff total to 1200, GSK said. This includes over 30 apprentice and 50 graduate roles.

Source: GlaxoSmithKline

 

Recent Videos
Behind the Headlines episode 6
CPHI Milan 2024: Highlighting the Benefits of Integrated Services
Behind the Headlines episode 5
Buy, Sell, Hold: Cell and Gene Therapy
Buy, Sell, Hold: Cell and Gene Therapy
Buy, Sell, Hold: Cell and Gene Therapy
Related Content